舒洛地特对糖尿病肾病患者尿足细胞排泄的影响  

Role of sulodoxide played in urinary podocyte excretion in patients with diabetic nephropathy

作　　者：龙香菊[1] 林珊[1] 江建青[1] 陈小红[1] 张鑫[2] 韦莉[1] 商文雅[1] 祝再然[1] 

机构地区：[1]天津医科大学总医院肾内科,300070 [2]天津医科大学总医院内分泌科,300070

出　　处：《中华内分泌代谢杂志》2013年第2期148-151,共4页Chinese Journal of Endocrinology and Metabolism

基　　金：天津市卫生局科研基金项目（2011WZ105）

摘　　要：通过观察糖尿病肾病患者肾活检标本肾小球足细胞特异性蛋白podocalyxin（PCX）的表达，及舒洛地特治疗前后尿中PCX阳性足细胞数变化，证实舒洛地特对糖尿病肾病肾小球足细胞有一定保护作用并对足细胞脱落可能有抑制作用。The podocalyxin expression in glomerulus in patients with diabetic nephropathy and urinary podocalyxin-positive podocytes were observed and determined before and after sulodexide treatment. The results demonstrated that sulodexide may protect the podocyte by inhibiting its detachment from glomerulus.

关 键 词：舒洛地特 糖尿病肾病 足细胞 

分 类 号：R587.2[医药卫生—内分泌]